ArticleFrontiers in oncology2025
Pleomorphic adenocarcinoma of the breast: a case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article comprehensively reports a case of pleomorphic adenocarcinoma of the breast, a rare breast salivary gland-type tumor. A mass with a maximum diameter of 3.2 cm was detected through ultrasound within the upper outer quadrant in a 74-year-old woman undergoing left breast total mastectomy and sentinel lymph node exploration. Microscopically, the central part of the tumor was mostly arranged in the solid structures, some of which were cribriform and contained blue-stained secretions, while the periphery of the tumor had striated and glandular duct-like arranged structures. Some tumor cells had visible nucleoli and nuclear fission, with sparse cytoplasm. Immunohistochemistry revealed ER (-), PR (-), HER-2 (0), Bcl-2 (+), P63 (-), Calponin (-), S100 (+), E-cadherin (+), and Ki-67 (20%+). The next-generation sequencing (NGS) assay revealed a missense mutation within exon 7 in PIK3CA, which is related to the treatment of breast cancer. The patient received 1 course of oral Capecitabine treatment after surgery and was followed up for 2 years with no recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.